Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lonafarnib

FDA-approved product (capsule, oral), marketed as Zokinvy.

Registered studies
39
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lonafarnib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hutchinson-Gilford progeria syndrome
  • Laminopathies
  • Progeria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Various alimentary tract and metabolism products
FDA pharmacologic class
Farnesyltransferase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

39registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lonafarnib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lonafarnib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

    NCT00539968 · start 2007-06

    Registered record
    Registry ID
    NCT00539968
    Conditions
    Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer
    Interventions
    Docetaxel plus lonafarnib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2007-06
    Completion
    2009-12
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer +1 more
    InterventionDocetaxel plus lonafarnib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria

    NCT00425607 · start 2007-05

    Registered record
    Registry ID
    NCT00425607
    Conditions
    Progeria; Hutchinson-Gilford Syndrome
    Interventions
    Lonafarnib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-05
    Completion
    2009-10
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgeria; Hutchinson-Gilford Syndrome
    InterventionLonafarnib
    PhasePhase 2
    Registry statusCompleted

  • Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

    NCT00281515 · start 2006-01

    Registered record
    Registry ID
    NCT00281515
    Conditions
    Epithelial Ovarian Cancer
    Interventions
    Lonafarnib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-01
    Completion
    2011-12
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpithelial Ovarian Cancer
    InterventionLonafarnib
    PhasePhase 2
    Registry statusCompleted

  • Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

    NCT00288444 · start 2006-01

    Registered record
    Registry ID
    NCT00288444
    Conditions
    Lung Cancer; Soft Tissue Sarcoma; Colorectal Carcinoma; Breast Cancer; Prostate Cancer
    Interventions
    Lonafarnib; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2006-01
    Completion
    2009-03
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Soft Tissue Sarcoma; Colorectal Carcinoma; Breast Cancer +1 more
    InterventionLonafarnib; Docetaxel
    PhasePhase 1
    Registry statusTerminated

  • PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas

    NCT00612651 · start 2005-10

    Registered record
    Registry ID
    NCT00612651
    Conditions
    Gliosarcoma; Glioblastoma; Anaplastic Astrocytoma
    Interventions
    Temodar and SCH 66336
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-10
    Completion
    2011-06
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGliosarcoma; Glioblastoma; Anaplastic Astrocytoma
    InterventionTemodar and SCH 66336
    PhasePhase 1
    Registry statusCompleted

  • Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

    NCT00109538 · start 2005-05

    Registered record
    Registry ID
    NCT00109538
    Conditions
    Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Myelodysplasia; Myelomonocytic
    Interventions
    Lonafarnib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2005-05
    Completion
    2008-08
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Myelodysplasia; Myelomonocytic
    InterventionLonafarnib; Placebo
    PhasePhase 3
    Registry statusTerminated

  • 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

    NCT00102635 · start 2005-01-20

    Registered record
    Registry ID
    NCT00102635
    Conditions
    Head and Neck Cancer
    Interventions
    Fenretinide (4-HPR); SCH66336
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2005-01-20
    Completion
    2006-11
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    InterventionFenretinide (4-HPR); SCH66336
    PhasePhase 1
    Registry statusTerminated

  • Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

    NCT00102648 · start 2004-12-21

    Registered record
    Registry ID
    NCT00102648
    Conditions
    Malignant Supratentorial Neoplasm; Recurrent Glioblastoma; Recurrent Gliosarcoma
    Interventions
    Lonafarnib; Temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2004-12-21
    Completion
    2025-12-01
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Supratentorial Neoplasm; Recurrent Glioblastoma; Recurrent Gliosarcoma
    InterventionLonafarnib; Temozolomide
    PhasePhase 1
    Registry statusActive not recruiting

  • Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas

    NCT00083096 · start 2004-03

    Registered record
    Registry ID
    NCT00083096
    Conditions
    Brain and Central Nervous System Tumors
    Interventions
    lonafarnib; temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2004-03
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors
    Interventionlonafarnib; temozolomide
    PhasePhase 1
    Registry statusUnknown

  • Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

    NCT00081510 · start 2003-12

    Registered record
    Registry ID
    NCT00081510
    Conditions
    Breast Cancer
    Interventions
    Lonafarnib; Placebo; anastrozole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-12
    Completion
    2009-05
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionLonafarnib; Placebo; anastrozole
    PhasePhase 2
    Registry statusCompleted

  • Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)

    NCT00073450 · start 2003-09

    Registered record
    Registry ID
    NCT00073450
    Conditions
    Carcinoma, Squamous Cell; Head and Neck Neoplasms
    Interventions
    Farnesyl Protein Transferase Inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2003-09
    Completion
    2004-06
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Squamous Cell; Head and Neck Neoplasms
    InterventionFarnesyl Protein Transferase Inhibitor
    PhasePhase 2
    Registry statusTerminated

  • Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

    NCT00068757 · start 2003-08

    Registered record
    Registry ID
    NCT00068757
    Conditions
    Breast Cancer
    Interventions
    trastuzumab; lonafarnib; paclitaxel; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-08
    Completion
    Not recorded
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiontrastuzumab; lonafarnib; paclitaxel; pharmacological study
    PhasePhase 1
    Registry statusCompleted

  • Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)

    NCT00050336 · start 2002-12

    Registered record
    Registry ID
    NCT00050336
    Conditions
    Carcinoma, Non-small-cell Lung; Metastases, Neoplasm
    Interventions
    Lonafarnib (SARASAR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2002-12
    Completion
    2004-03
    Enrolment
    702

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-small-cell Lung; Metastases, Neoplasm
    InterventionLonafarnib (SARASAR)
    PhasePhase 3
    Registry statusTerminated

  • Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

    NCT00047502 · start 2002-11-01

    Registered record
    Registry ID
    NCT00047502
    Conditions
    Chronic Myelogenous Leukemia
    Interventions
    Lonafarnib (SCH66336); Imatinib Mesylate (Gleevec)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-11-01
    Completion
    2006-04-10
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myelogenous Leukemia
    InterventionLonafarnib (SCH66336); Imatinib Mesylate (Gleevec)
    PhasePhase 1
    Registry statusCompleted

  • SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors

    NCT00015899 · start 2002-01

    Registered record
    Registry ID
    NCT00015899
    Conditions
    Brain and Central Nervous System Tumors
    Interventions
    lonafarnib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-01
    Completion
    2007-03
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors
    Interventionlonafarnib
    PhasePhase 1
    Registry statusCompleted